Back to top

Regentis Biomaterials (NYSE American: RGNT) Targets $3B Cartilage Repair Market with Cell-Free Gelrin C

Austin, Texas, United States, July 30th, 2026, FinanceWire Regentis Biomaterials (NYSE American: RGNT) is positioning its Gelrin C hydrog...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE: